Efficacy of New Injectable Cholesterol Lowering Medications Versus Statin Drugs in Treating Hyperlipidemia

Introduction: Cardiovascular disease is the leading global cause of death, with elevated low-density lipoprotein cholesterol (LDL-C) as a major modifiable risk factor. 
Purpose: The purpose of this study was to explore and compare the role of cholesterol-lowering medications, with a focus on PCSK9 inhibitors, and statin drugs. 
Methods: This retrospective mixed-methods study compared the effectiveness of statins with newer injectable lipid-lowering therapies. Data was drawn from 50 patient records and supplemented with semi-structured provider interviews to explore clinical decision-making. Results: Injectable therapies reduced LDL-C by an average of 45.6%, exceeding the 39.5% reduction achieved with statins. Predictors for injectable use included elevated lipoprotein(a), high ASCVD risk scores, and significant coronary calcium scores. 
Conclusion: Injectable lipid-lowering agents may offer greater benefits for high-risk patients or those intolerant to statins. Findings support individualized treatment strategies to improve hyperlipidemia management and reduce cardiovascular events. 

Keywords 
Cardiovascular disease, hyperlipidemia, statins, PCSK9 inhibitors, Praluent, Repatha, Leqvio, LDL-C reduction, lipoprotein(a), ASCVD risk, cholesterol-lowering therapy, provider perspectives, emerging lipid medications